Senseonics Stock Down Despite New FDA Approval for Eversense 365

Senseonics Holdings, Inc. (SENS) , along with Ascensia Diabetes Care, announced the receipt of the FDA's clearance for the next-generation Eversense 365 continuous glucose monitoring (CGM) system for people with Type 1 and Type 2 diabetes aged 18 years and above. Eversense 365 has been cleared as an integrated CGM (iCGM) system, indicating that it can integrate with compatible medical devices, including insulin pumps, as part of an automated insulin delivery system. Ascensia, a subsidiary of PHC Holdings Co ...